Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551730 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
A Phase 2 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03551730 is a Phase 2 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT03551730, a Phase 2 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
Interventions
- DRUG Placebo
- COMBINATION_PRODUCT PRT064445/Enoxaparin
- COMBINATION_PRODUCT Placebo/Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551730
The ClinicalTrials.gov registry entry for NCT03551730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03551730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03551730 about?
NCT03551730 is a clinical study titled "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)". The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
What is the current status of trial NCT03551730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2012-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT03551730?
The interventions under investigation include: Placebo (DRUG), PRT064445/Enoxaparin (COMBINATION_PRODUCT), Placebo/Enoxaparin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03551730?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.